CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
工程化细胞免疫疗法在癌症及其他疾病中的应用
英文原题：Engineered cellular immunotherapies in cancer and beyond.
查看英文原题
Engineered cellular immunotherapies in cancer and beyond.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
今年是嵌合抗原受体（CAR）修饰T细胞治疗难治性白血病十周年。基因工程T细胞在多种血液肿瘤中的广泛商业批准为其他类型癌症患者带来了希望，而人类基因组工程与细胞治疗技术的融合为产生一类新的细胞治疗药物提供了巨大潜力。在这篇综述中，我们讨论了癌症细胞免疫治疗的目标、该领域面临的关键挑战以及为克服这些障碍而出现的新兴策略。最后，我们概述了癌症领域的进展如何为其他疾病的细胞免疫治疗铺平道路。
展开英文摘要原文
This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-modified T cells for refractory leukemia. The widespread commercial approval of genetically engineered T cells for a variety of blood cancers offers hope for patients with other types of cancer, and the convergence of human genome engineering and cell therapy technology holds great potential for generation of a new class of cellular therapeutics.
In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing the field and exciting strategies that are emerging to overcome these obstacles.
Finally, we outline how developments in the cancer field are paving the way for cellular immunotherapeutics in other diseases.
论文信息
- 作者
- Finck AV、Blanchard T、Roselle CP、Golinelli G、June CH
- 第一作者单位
- Center for Cellular Immunotherapies, Perelman School of Medicine, and Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA. finckam@pennmedicine.upenn.edu.United States
- 通讯作者单位
- Center for Cellular Immunotherapies, Perelman School of Medicine, and Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.United States
- 文献类型
- 综述 · 美国政府（非公共卫生署）资助研究 · 美国 NIH 资助研究 · 非美国政府资助研究
- 期刊
- Nature medicine2022 Apr
- 原文标识
- PubMed 35440724 · DOI 10.1038/s41591-022-01765-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →